Ohcanbohtosat - Véronique Dièras

Aiddostahte ozu
  1. 1
    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer Dahkki Jean Paul Guastalla, Véronique Dièras

    Almmustuhtton 2003
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Expert perspectives on biosimilar monoclonal antibodies in breast cancer

    Expert perspectives on biosimilar monoclonal antibodies in breast cancer Dahkki Javier Cortés, Giuseppe Curigliano, Véronique Dièras

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer

    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer Dahkki Fanny Le Du, Véronique Dièras, Giuseppe Curigliano

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients Dahkki D.W. Miles, Véronique Dièras, Javier Cortés, Anja Duenne, Jingbo Yi, Joyce O’Shaughnessy

    Almmustuhtton 2013
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen

    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen Dahkki Karim Fizazi, Bernard Asselain, Anne Vincent‐Salomon, Michel Jouve, Véronique Dièras, Thao Palangié, Philippe Beuzeboc, Thierry Dorval, P Pouillart

    Almmustuhtton 1996
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study

    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study Dahkki Véronique Dièras, Alain Lortholary, Valérie Laurence, R. Delva, V. Girre, Alain Livartowski, Sylvie Assadourian, Dorothée Sémiond, Jean‐Yves Pierga

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer Dahkki Paul Cottu, Jamil Asselah, Marick Laé, J-Y Pierga, Véronique Dièras, L. Mignot, Brigitte Sigal‐Zafrani, Anne Vincent‐Salomon

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    New approaches for improving outcomes in breast cancer in Europe

    New approaches for improving outcomes in breast cancer in Europe Dahkki Angelo Di Leo, Giuseppe Curigliano, Véronique Dièras, Luca Malorni, Christos Sotiriou, Charles Swanton, Alastair M. Thompson, Andrew Tutt, Martine Piccart

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer Dahkki Guy Jérusalem, Angelica Fasolo, Véronique Dièras, Fátima Cardoso, Jonas Bergh, Luc Vittori, Yufen Zhang, Cristian Massacesi, Tarek Sahmoud, Luca Gianni

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy Dahkki Ahmad Awada, Luc Dirix, Luís Manso, Binghe Xu, T Luu, Véronique Dièras, Dawn L. Hershman, V. Agrapart, Revathi Ananthakrishnan, Elżbieta Starosławska

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer Dahkki Valentina Guarneri, David Miles, Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, Pierfranco Conté

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp... Dahkki Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis

    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis Dahkki Véronique Dièras, Nadia Harbeck, G. Thomas Budd, Joel K. Greenson, Alice E. Guardino, Meghna Samant, Nataliya Chernyukhin, Melanie C. Smitt, Ian E. Krop

    Almmustuhtton 2014
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience Dahkki L. Staudacher, P. Cottu, Véronique Dièras, Anne Vincent‐Salomon, M.N. Guilhaume, Lu Wang, Thierry Dorval, Philippe Beuzeboc, L. Mignot, Jean‐Yves Pierga

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Survival of breast cancer patients with meningeal carcinomatosis

    Survival of breast cancer patients with meningeal carcinomatosis Dahkki H. Gauthier, M.N. Guilhaume, François‐Clément Bidard, Jean‐Yves Pierga, V. Girre, Paul Cottu, Valérie Laurence, Alain Livartowski, L. Mignot, Véronique Dièras

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age

    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age Dahkki Jean‐Yves Pierga, V. Girre, Valérie Laurence, Bernard Asselain, Véronique Dièras, M Jouve, Philippe Beuzeboc, Alain Fourquet, Claude Nos, Brigitte Sigal‐Zafrani, P Pouillart

    Almmustuhtton 2004
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC Dahkki P. Fumoleau, B Chevallier, Pierre Kerbrat, Yvan Krakowski, J. L. Misset, C. Maugard-Louboutin, Véronique Dièras, N. Azli, Nathalie Bougon, A. Riva, Henri Roché

    Almmustuhtton 1996
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic... Dahkki Jean‐Yves Pierga, David Hajage, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Véronique Dièras, Emilie Rolland, L. Mignot, Claire Mathiot, François‐Clément Bidard

    Almmustuhtton 2011
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells

    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells Dahkki François‐Clément Bidard, Anne Vincent‐Salomon, Brigitte Sigal‐Zafrani, Véronique Dièras, Claire Mathiot, L. Mignot, Jean Paul Thiery, Xavier Sastre‐Garau, Jean‐Yves Pierga

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC Dahkki Véronique Dièras, B Chevallier, Pierre Kerbrat, I. Krakowski, Henri Roché, JL Misset, M-A. Lentz, N. Azli, M Murawsky, A. Riva, P Pouillart, P. Fumoleau

    Almmustuhtton 1996
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: